2016
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics
Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12: 721-731. PMID: 27140427, DOI: 10.1080/17425255.2016.1183644.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect acting antiviralsOpioid use disorderDrug interactionsUse disordersHCV direct acting antiviralsNovel direct acting antiviralsHepatitis C virus infectionHepatitis C therapeuticsHigh HCV prevalenceC virus infectionMedication-assisted therapyPharmacodynamic drug interactionsSpecific drug combinationsDrug package insertsHCV prevalenceHCV infectionHCV treatmentOpioid withdrawalActing antiviralsCombination regimenPharmacodynamic assessmentConcurrent administrationDrug levelsHigh prevalenceVirus infection
2013
Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance
Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance. Antimicrobial Agents And Chemotherapy 2013, 57: 6154-6157. PMID: 24080665, PMCID: PMC3837895, DOI: 10.1128/aac.01229-13.Peer-Reviewed Original ResearchConceptsEVG/COBIBaseline valuesEffect of elvitegravirOpioid-dependence therapiesHIV-seronegative subjectsConcentration-time curveChronic methadone maintenanceDependence therapyOpioid withdrawalMethadone pharmacokineticsDosing periodMethadone maintenanceHistorical controlsPharmacodynamic studiesPharmacokinetic parametersMethadoneCobicistatElvitegravirMean areaAUCtauPharmacodynamicsCmaxSubjectsCOBISteady-state evaluationThe Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluationPharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2010
Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 511-514. PMID: 20672450, PMCID: PMC4841260, DOI: 10.1097/qai.0b013e3181d3cad3.Peer-Reviewed Original ResearchConceptsLPV/rBuprenorphine/naloxoneHIV-seronegative subjectsLopinavir/ritonavirOpioid withdrawalPharmacokinetic interactionsDaily lopinavir/ritonavirDaily LPV/rSteady-state pharmacokinetic evaluationBuprenorphine pharmacokineticsR administrationDosage modificationNaloxone concentrationsHistorical controlsPharmacodynamic responseAUC0-24hBaseline valuesPharmacokinetic evaluationNaloxonePharmacokinetic studySignificant differencesRitonavirNLXCmaxClearance
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysicians